Patrick O'Shaughnessy × Andrew Huberman

Sleep is the near-term neurotechnology wedge because users already accept physiological measurement, while an eye mask reportedly measures REM, induces sleep-promoting eye movements, and amplifies REM, with related technology expected in roughly seven to 12 months.Huberman predicts Meta, OpenAI, Anthropic, and Elon’s Neuralink effort will converge on neural read/write biotech, but missing models of memory and thought, plus a possible 2027-28 downturn in optimization content, remain key risks.

Peter Diamandis × Salim Ismail × Dave Blundin × Alexander Wissner-Gross × Richard Socher

Recursive’s $670 million raise, backed by Google Ventures, Greycroft, Nvidia, and AMD, targets weak recursive improvement as AI-generated code increasingly enters system design.Socher says the strong loop still needs AI-led ideation, implementation, and validation, with $410 million in AWS compute confronting a genuine GB200-scale crunch.Sonnet 5.5’s reportedly 70% Terminal Bench 4.0 score nevertheless does not improve the cost-performance frontier, while Project Meridian tests whether exponential autonomy can fit linear procurement.

Graig Suvannavejh × Sam Fazeli × Eric Schmidt × Brian Skorney

Biotech’s 27% XBI gain through September masks a punishing ownership unwind, as underowned and heavily shorted names offset specialist-fund selling.Regeneron-Sanofi’s $1 billion upfront and AstraZeneca’s $2 billion Summit investment show strategic capital is flowing, but HARMONi-3 remains a potentially historic binary event.China-origin deals and Lilly’s obesity data sharpen competition, while financing, durability, tolerability, and endpoint risk still dictate outcomes.

Jonathan Siddharth × Molly O'Shea

Healthcare AI has crossed O'Shea’s threshold for measurable impact, with biological and chemical models, laboratory robotics and simulations targeting drug development’s high failure rates.After a decade building licenses, networks and care infrastructure, Devoted Health tripled in size, halved operating expenses and significantly increased EBITDA, while China’s rising pharmaceutical research share leaves domestic research and regulatory capacity as risks to monitor.

Nathan Labenz × Prakash Narayanan × Jeremie Harris × Edouard Harris × Steve Hou × Joel Borgen × Daniel McKinnon

Trump-Xi contact could create an AI-crisis hotline, but without pre-vetted verification tools, an incident could trigger a demand to shut down a large cluster.Hyperscalers charge at least two to three times neo-cloud GPU prices; Gamo’s o3 loop found a 91-kilobase deletion, while Opus 5.5 scored about 50% on RareBench versus roughly 10% for LIRICAL.

Peter Diamandis × Salim Ismail × Dave Blundin × Alexander Wissner-Gross × Ben Lamm

Colossal is now worth over $10 billion with more than four spin-offs, while AI connects fragmented research and addresses 40–60% replication failure through standardized language.That data infrastructure may matter more than the model itself as comparative genomics spans thousands of genomes.Colossal has surpassed 300 edits at over 90% efficiency and is testing 1,000, with large-fragment DNA synthesis and a fully extrauterine mammalian birth within 24 months as catalysts amid ethical and regulatory constraints.

Daniel Ek

Spotify passed 700 million active users and 300 million premium subscribers; Daniel Ek became executive chairman January 1 and returned to building.Neko's $499 unit-economic-positive visit combines 53 blood markers, 6,000 images and clinician review in roughly an hour.Over 100,000 scans found serious, previously undiagnosed conditions in roughly 1% of members; population outcomes and budget effects remain unresolved.

Sam Fazeli × Yaron Werber × Brian Skorney × Matt Gline

Biotech’s healthy headline tape masked long-short degrossing and rate sensitivity, while 22 IPOs and record-period average proceeds showed primary-market resilience.MFN may rebalance global contributions through revenue sharing rather than simply cut U.S. prices, but Europe could restrict access or favor cheaper Chinese drugs; meanwhile, durable VK2735 efficacy, Celldex safety and Vertex’s interim analysis define catalysts.

Josh Schimmer × Eric Schmidt × Paul Matteis × Adam Feuerstein

XBI fell roughly 4% month to date and 9%-10% from its highs, but remained up about 30% for the year, suggesting nervous consolidation rather than a broken thesis.Xenon’s nearly 30% selloff after pausing depression enrollment came despite no clinical hold and about 360 patients enrolled, showing how bounded safety data can become a franchise scare.Sionna’s failed add-on study reinforced Vertex’s cystic-fibrosis moat, while a switch study remains the key test.

Yiwen × Matteo Franceschetti × Alex Zatarain

Eight Sleep以实时响应而非单纯追踪形成差异化，AI可在睡眠期间调节温度、床头高度和声音。专利、自有传感器与专有数据构成护城河，中国是增长最快市场；FDA睡眠呼吸暂停检测与缓解审批是催化剂，但准确率仍未按任务明确。